Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

171261

Sigma-Aldrich

Dorsomorphin

≥95% (HPLC), liquid, AMPK inhibitor, Calbiochem

Sinónimos:

InSolution AMPK Inhibitor, Compound C, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C24H25N5O
Número de CAS:
Peso molecular:
399.49
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Nombre del producto

AMPK Inhibitor, Compound C, InSolution, ≥95%, 10 mM, AMPK Inhibitor

Nivel de calidad

Ensayo

≥95% (HPLC)

Formulario

liquid

fabricante / nombre comercial

Calbiochem®

condiciones de almacenamiento

OK to freeze
desiccated (hygroscopic)
protect from light

Condiciones de envío

wet ice

temp. de almacenamiento

2-8°C

cadena SMILES

[n]21ncc(c2ncc(c1)c4ccc(cc4)OCCN5CCCCC5)c3ccncc3

InChI

1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2

Clave InChI

XHBVYDAKJHETMP-UHFFFAOYSA-N

Descripción general

A cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo.

Acciones bioquímicas o fisiológicas

Cell permeable: yes
EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
Primary Target
AMPK
Product competes with ATP.
Reversible: yes
Target IC50: 25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively

Envase

Packaged under inert gas

Advertencia

Toxicity: Irritant (B)

Forma física

Supplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO.

Reconstitución

Following initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C.

Otras notas

Hao, J., et al. 2010. ACS Chem.Biol.5, 245.
Kim, E.K., et al. 2004. J. Biol. Chem.279, 19970.
Lee, M., et al. 2003. J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003. Cell115, 577.
Fryer, L.G., 2002. FEBS Lett.531, 189.
Zhou, G., et al. 2001. J. Clin. Invest.108, 1167.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

188.6 °F - closed cup - (Dimethylsulfoxide)

Punto de inflamabilidad (°C)

87 °C - closed cup - (Dimethylsulfoxide)


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yao-Yao Chang et al.
Frontiers in immunology, 13, 820524-820524 (2022-03-01)
P2Y1 receptor is a G-protein-coupled receptor that plays a critical role in the immune response of inflammatory bowel diseases. However, its regulatory effects on CD4+ T cell response have not been fully elucidated. The study aimed to characterize the role
Karina Krotova et al.
Human gene therapy, 31(19-20), 1124-1131 (2020-06-05)
Adeno-associated virus (AAV)-based gene therapy is undergoing major expansion into clinical practice, with two treatments currently being granted Food and Drug Administration (FDA) approval. However, the presence of pre-existing neutralizing antibodies (NAB) is one of the significant hurdles for the
Reetta A E Eriksson et al.
Frontiers in medicine, 9, 1052318-1052318 (2022-12-31)
Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We compared several
Ernesto Pena Calderin et al.
Molecular metabolism, 66, 101637-101637 (2022-11-19)
Physical activity has been shown to reduce the risk of CVD mortality in large-cohort longitudinal studies; however, the mechanisms underpinning the beneficial effects of exercise remain incompletely understood. Emerging data suggest that the risk reducing effect of exercise extends beyond
David P Santos et al.
Methods in molecular biology (Clifton, N.J.), 1538, 53-66 (2016-12-13)
Human embryonic stem cells (ESCs) are characterized by their unique ability to self-renew indefinitely, as well as to differentiate into any cell type of the human body. Induced pluripotent stem cells (iPSCs) share these salient characteristics with ESCs and can

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico